---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003866"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:09:53.184104+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Travere reports preliminary Q4 2023 net product sales ~$40M, FILSPARI sales $15M; cash $567M

## Summary
- Preliminary Q4 2023 net product sales from continuing ops ~$40M; FY 2023 ~$128M.
- FILSPARI net sales Q4 ~$15M (launch-to-date ~$30M); 459 new patient start forms in Q4.
- Cash, cash equivalents & marketable securities ~$567M; expected to fund operations into 2028.
- sNDA for full FILSPARI approval in IgAN on track for Q1 2024; CHMP opinion also expected Q1 2024.
- Pivotal Phase 3 HARMONY study for pegtibatinase in HCU initiated; topline results expected in 2026.

## SEC filing metadata
- accession: 0001193125-24-003866
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/d87492d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003866
- JSON: https://secwatch.observer/filing/0001193125-24-003866.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003866.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported fiscal year 2023 results: revenue approximately $128 million.
  - Period: fiscal year 2023
  - Revenue: approximately $128 million
  - Result: preliminary results
  source text: For the fiscal year 2023, the Company expects net product sales from continuing operations to be approximately $128 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm
- Earnings Releases
  Travere Therapeutics, Inc. reported fourth quarter of 2023 results: revenue $15 million.
  - Period: fourth quarter of 2023
  - Revenue: $15 million
  - Result: preliminary results
  source text: the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm
- Earnings Releases
  Travere Therapeutics, Inc. reported fourth quarter of 2023 results: revenue $15 million.
  - Period: fourth quarter of 2023
  - Revenue: $15 million
  - Result: preliminary results
  source text: Preliminary net product sales of FILSPARI in the fourth quarter of 2023 were $15 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.